Ssa. Fenton et al., HEMODIALYSIS VERSUS PERITONEAL-DIALYSIS - A COMPARISON OF ADJUSTED MORTALITY-RATES, American journal of kidney diseases, 30(3), 1997, pp. 334-342
Although kidney transplantation is the preferred treatment method for
patients with ESRD, most patients are placed on dialysis either while
awaiting transplantation or as their only therapy, The question of whi
ch dialytic method provides the best patient survival remains unresolv
ed, Survival analyses comparing hemodialysis and continuous ambulatory
peritoneal dialysis/continuous cyclic peritoneal dialysis (CAPD/CCPD)
, a newer and less costly dialytic modality, have yielded conflicting
results, Using data obtained from the Canadian Organ Replacement Regis
ter, we compared mortality rates between hemodialysis and CAPD/CCPD am
ong 11,970 ESRD patients who initiated treatment between 1990 and 1994
and were followed-up for a maximum of 5 years, Factors controlled for
include age, primary renal diagnosis, center size, and predialysis co
morbid conditions, The mortality rate ratio (RR) for CAPD/CCPD relativ
e to hemodialysis, as estimated by Poisson regression, was 0.73 (95% c
onfidence interval: 0.68 to 0.78), No such relationship was found when
an intent-to-treat Cox regression model was fit, Decreased covariable
-adjusted mortality for CAPD/CCPD held within all subgroups defined by
age and diabetes status, although the RRs increased with age and diab
etes prevalence, The increased mortality on hemodialysis compared with
CAPD/CCPD was concentrated in the first 2 years of follow-up, Althoug
h continuous peritoneal dialysis was associated with significantly low
er mortality rates relative to hemodialysis after adjusting for known
prognostic factors, the potential impact of unmeasured patient charact
eristics must be considered, Notwithstanding, we present evidence that
CAPD/CCPD, a newer and less costly method of renal replacement therap
y, is not associated with increased mortality rates relative to hemodi
alysis, (C) 1997 by the National Kidney Foundation, Inc.